RobertErnestBelletMD

PubMed

• 32 citations
  Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin ® , in resistant solid tumor malignancies
  Paula M. Fracasso, Joel Picus, Jonathan Wildi, Sherry A. Goodner, Allison N. Creekmore, Feng Gao, Ramaswamy Govindan, Matthew J. Ellis, Benjamin R. Tan, Gerald P. Line...> ;Cancer Chemotherapy and Pharmacology. 2009 Feb 1
• Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel (Taxoprexin) in resistant solid tumor malignancies.
  Fracasso PM, Govindan R, Ellis MJ, Tan BR, Linette GP, Picus J, Goodner SA, Jones S, Bellet RE, Burris HA> ;J. Clin. Oncol.. 2006-06-20
• Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC).
  Bellet R, Carducci M, Petrylak D, Kasimis B, Irwin D, Modiano M, Mansour R, Axelrod R, Doukas M> ;J. Clin. Oncol.. 2004-07-15
• 1 citations
  DOCETAXEL IN COMBINATION WITH FLUOROURACIL : STUDY DESIGN AND PRELIMINARY RESULTS
  E. K. Rowinsky, Lon Smith, Gladys Rodriguez, L White, Ronald Drengler, D. Von Hoff, N. W. Peacock, C. Aylesworth, H. A. Burris, Peter M. Ravdin, Robert E. Bellet> ;Oncology. 1997 Jun 1
• 312 citations
  Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
  Vicente Valero, Frankie A. Holmes, Ronald S. Walters, Richard L. Theriault, Laura Esparza, Giuseppe Fraschini, Gustavo Fonseca, Robert E. Bellet, Aman U. Buzdar, Gabri...> ;Journal of Clinical Oncology. 1995 Dec 1
• 270 citations
  Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
  Peter M. Ravdin, Howard A. Burris, Gayle Cook, Peter D. Eisenberg, Michael P. Kane, William A. Bierman, James A. Mortimer, Eric Genevois, Robert E. Bellet> ;Journal of Clinical Oncology. 1995 Dec 1
• 114 citations
  Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials.
  Edward F. McCiay, Michael J. Mastrangelo, David Berd, Robert E. Bellet> ;International Journal of Cancer. 1992 Feb 20
• 1 citations
  Protection of Central Nervous System Metastases From Systemic Chemotherapy by Adrenal Corticosteroids
  Robert E. Bellet> ;Journal of the National Cancer Institute. 1991 May 1
• 92 citations
  The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
  Edward F. McClay, Michael J. Mastrangelo, John D. Sprandio, Robert E. Bellet, David Berd> ;Cancer. 1989 Apr 1
• 1 citations
  Preoperative evaluation of the oncology patient.
  Edward F. McClay, Robert E. Bellet> ;The Medical Clinics of North America. 1987 May 1
• 14 citations
  Frequency of occult residual melanoma after excision of a clinically positive regional lymph node
  Michael Kane, Edward F. McClay, Robert E. Bellet> ;Annals of Surgery. 1987 Jan 1
• 40 citations
  Primary choroidal and cutaneous melanomas occurring in a patient with the B-K mole syndrome phenotype.
  Robert E. Bellet, Jerry A. Shields, Evelina A. Bernardino> ;American Journal of Ophthalmology. 1980 Apr 1
• 4 citations
  Effect of 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea Adjuvant Therapy on the Immune Response of Patients with Malignant Melanoma
  David Berd, Eileen J. Wilson, Robert E. Bellet, Michael J. Mastrangelo> ;Cancer Research. 1979 Nov 1
• 52 citations
  Evaluation of a “Nude” Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agents
  Robert E. Bellet, Victoria Danna, Michael J. Mastrangelo, David Berd> ;Journal of the National Cancer Institute. 1979 Nov 1
• 7 citations
  Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
  Robert E. Bellet, Robert B. Catalano, Michael J. Mastrangelo, David Berd> ;Medical and Pediatric Oncology. 1978 Jan 1
• 5 citations
  A phase II evaluation of bacillus calmette‐guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma
  J. Frederick Laucius, Yogish A. Patel, Charles J. Lusch, Lawrence S. Koons, Robert E. Bellet, Michael J. Mastrangelo> ;Medical and Pediatric Oncology. 1977 Jan 1
• 46 citations
  CRITICAL REVIEW OF PREVIOUSLY REPORTED CLINICAL TRIALS OF CANCER IMMUNOTHERAPY WITH NON-SPECIFIC IMMUNOSTIMULANTS*
  Michael J. Mastrangelo, David Berd, Robert E. Bellet> ;Annals of the New York Academy of Sciences. 1976 Sep 1
• 8 citations
  BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
  Michael E. Pliskin, Michael J. Mastrangelo, Robert E. Bellet, Jane Berkelhammer> ;Oral Surgery, Oral Medicine, and Oral Pathology. 1976 Jul 1
• 9 citations
  Cryptococcal Pleural Effusion
  Jerry D. Smilack, Robert E. Bellet, William T. Talman> ;JAMA. 1975 May 12
• 10 citations
  Estrogen-induced Hypernephroma
  Robert E. Bellet, Alfonse P. Squitieri> ;The Journal of Urology. 1974 Aug 1
• 27 citations
  A phase I study of emetine hydrochloride (NSC 33669) in solid tumors.
  Michael J. Mastrangelo, Theodor B. Grage, Robert E. Bellet, Arthur J. Weiss> ;Cancer. 1973 May 1
• A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
  Petit, T., Aylesworth, C., Burris, H., Ravdin, P., Rodriguez, G., Smith, L., Peacock, N., Smetzer, L., Bellet, R., Von Hoff, D. D., Rowinsky, E. K.> ;Ann Oncol. 1999 Feb
• Viral hemorrhagic septicemia (VHS) of the rainbow trout bred in France.
  Bellet, R.> ;Ann N Y Acad Sci. 1965 Aug 10
• Phase I study of ICRF-159 (NSC-129943) in human solid tumors.
  Bellet, R. E., Mastrangelo, M. J., Dixon, L. M., Yarbro, J. W.> ;Cancer Chemother Rep. 1973 Apr 01
• Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
  Bellet, R. E., Mastrangelo, M. J., Engstrom, P. F., Strawitz, J. G., Weiss, A. J., Yarbro, J. W.> ;Cancer Chemother Rep. 1974 Mar 01
• Join now to see all